Author Archives: Kevin Perez

Prometic to Advance IPF and Other Anti-fibrotic Therapies in Clinical Testing via Partnership in China

Prometic recently announced a financial agreement and partnership with Shenzhen Royal Asset Management (SRAM) to develop, manufacture, and commercialize several of its anti-fibrotic products in China, including PBI-4050 for idiopathic pulmonary fibrosis (IPF). PBI-4050 is an anti-fibrotic oral drug, which has demonstrated positive results in a Phase 2 study (NCT02538536) in patients…